查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771542

血友病市場規模、佔有率、趨勢分析報告：按疾病類型、治療類型、治療方法、分銷管道、地區和細分市場進行預測，2025 年至 2030 年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

血友病市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球血友病市場規模預計到2030年將達到210.7億美元，2025年至2030年的複合年成長率為6.91%。

用於治療血友病的基因療法和單株抗體的核准以及正在研發的幾種此類候選藥物是市場成長的主要驅動力，同時由於死亡率下降，血友病患者的預期平均壽命也在增加。

控制血友病的新型療法的開發和上市正在推動市場成長。例如，2020年4月，美國食品藥物管理局（FDA）核准了基因工程產品Sevenfact [凝血因子VIIa（重組）-jncw]，作為控制青少年（12歲及以上）和成年人出血發作的治療選擇。此外，BioMarin的A型血友病A治療藥物Roctavian僅在歐洲核准，而CSL的Hemgenix（etranacogene dezaparvovec-drib）在美國和歐洲都核准。 BioMarin的Roctavian先前被美國食品藥物管理局（FDA）駁回，目前正在接受審查，其PDUFA（處方藥使用者付費法案）的截止日期為2023年6月30日。

大型公司正專注於新產品開發和策略聯盟，以擴大其地理影響力。例如，2022年4月，諾和諾德公司與加拿大血液服務中心合作，增強了其Esperoct和Zonovate的產品陣容，這兩款產品均作為治療甲型血友病的藥物上市。此外，2023年2月，賽諾菲公司獲得美國食品藥物管理局（FDA）核准其用於治療A型血友病。

然而，在中國和印度等新興國家，輕度至中度病例的診斷延遲是一個重大阻礙因素。市場面臨的另一個重大挑戰是，由於高成本且缺乏長期數據，基因治療的可近性可能存在問題。例如，HemGenics 公司的療法（於 2022 年核准）每劑售價高達 350 萬美元，是全球最昂貴的治療方法。

血友病市場報告重點

  • 由於A型血友病的A型血友病A型血友病將在2024年佔據血友病市場的最大佔有率。由於基因療法的核准，該細分市場預計在預測期內也將實現最高的複合年成長率。
  • 根據銷售管道，由於該疾病需要專門的治療，預計專業藥局將在 2024 年佔據最大的市場佔有率。
  • 根據治療方法，因子替代療法在 2024 年佔據血友病市場的最大佔有率，因為它是用於預防和按需治療的主要治療方法。
  • 由於主要企業的存在、監管支持、患者意識和有利的資金支持，北美將成為 2024 年血友病市場收益最高的地區。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 血友病市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 血友病市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 管道分析

第4章血友病市場：疾病類型估計與趨勢分析

  • 2024 年及 2030 年疾病類型市場佔有率
  • 細分儀表板
  • 全球血友病市場：疾病類型展望
  • 2018-2030年市場規模、預測與趨勢分析
    • A型血友病A
    • B型血友病
    • 其他

第5章血友病市場：治療類型估計與趨勢分析

  • 2024 年和 2030 年治療類型市場佔有率
  • 細分儀表板
  • 全球血友病市場按治療類型展望
  • 2018-2030年市場規模、預測與趨勢分析
    • 一經請求
    • 治療
    • 預防

第6章血友病市場：治療方法評估與趨勢分析

  • 2024 年和 2030 年治療方法市場佔有率
  • 細分儀表板
  • 全球血友病市場：治療方法展望
  • 2018-2030年市場規模、預測與趨勢分析
    • 因子替代療法
    • 去氨加壓素和纖維蛋白膠
    • 基因治療和單株抗體

第7章血友病市場：通路評估與趨勢分析

  • 2024年及2030年分銷通路市場佔有率
  • 細分儀表板
  • 全球血友病市場（按分銷管道）
  • 2018-2030年市場規模、預測與趨勢分析
    • 醫院藥房
    • 專業藥房

第8章血友病市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 細分儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Takeda Pharmaceutical Company Limited.
    • CSL Behring
    • Pfizer Inc.
    • Bayer AG
    • BioMarin
    • Spark Therapeutics, Inc.
    • Sanofi
    • F. Hoffmann La-Roche Ltd
    • Novo Nordisk A/S
    • Octapharma AG.
Product Code: 978-1-68038-989-0

Hemophilia Market Growth & Trends:

The global hemophilia market size is estimated to reach USD 21.07 billion by 2030, registering a CAGR of 6.91% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights:

  • The type A segment held the largest share of the hemophilia market in 2024, owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy.
  • Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2024, attributable to the specialized nature of the treatment required for the condition
  • By therapy, factor replacement therapy held the largest share of the hemophilia market in 2024, as it is the major form of treatment used in both prophylaxis and on-demand treatment.
  • North America was the largest revenue-generating region in the hemophilia market in 2024, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Therapy
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Treatment
    • 2.2.3. Therapy
    • 2.2.4. Distribution Channel
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hemophilia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis
      • 3.4.1.1. Phase 1
      • 3.4.1.2. Phase 2
      • 3.4.1.3. Phase 3

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Hemophilia Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 4.4.1. Hemophilia A
      • 4.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Hemophilia B
      • 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

  • 5.1. Treatment Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hemophilia Market by Treatment Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 5.4.1. On-demand
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Cure
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Prophylaxis
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

  • 6.1. Therapy Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Hemophilia Market by Therapy Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 6.4.1. Factor Replacement Therapy
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.2. Plasma derived Factor Concentrates estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.2. Factor VIII
          • 6.4.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
        • 6.4.1.2.3. Factor IX
          • 6.4.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.3. Recombinant Factor Concentrates
        • 6.4.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.1. Factor VIII
            • 6.4.1.3.1.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.2. Factor VII
            • 6.4.1.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
          • 6.4.1.3.1.3. Factor IX
            • 6.4.1.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Desmopressin & Fibrin sealants
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Gene Therapy & Monoclonal Antibodies
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Hemophilia Market by Gender Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 7.4.1. Hospital Pharmacies
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Specialty Pharmacies
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Takeda Pharmaceutical Company Limited.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. CSL Behring
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Pfizer Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Bayer AG
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. BioMarin
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Spark Therapeutics, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Sanofi
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. F. Hoffmann La-Roche Ltd
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Novo Nordisk A/S
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Octapharma AG.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 19 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 24 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 27 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 32 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 35 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 36 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 39 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 40 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 43 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 44 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 47 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 48 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 51 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 52 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 56 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 64 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 65 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 68 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 69 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 71 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 72 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 73 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 77 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 80 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 81 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 84 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 85 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 89 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 90 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • Table 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global hemophilia market- Key market driver analysis
  • Fig. 7 Global hemophilia market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global hemophilia market - Porter's analysis
  • Fig. 10 Global hemophilia market - PESTEL analysis
  • Fig. 11 Global hemophilia market type outlook key takeaways
  • Fig. 12 Global hemophilia market: Type movement analysis
  • Fig. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
  • Fig. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 16 Global hemophilia market treatment outlook key takeaways
  • Fig. 17 Global hemophilia market: Treatment Type movement analysis
  • Fig. 18 On-demand market estimates, 2018 - 2030 (USD Million)
  • Fig. 19 Cure market estimates, 2018 - 2030 (USD Million)
  • Fig. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
  • Fig. 21 Global hemophilia market therapy outlook key takeaways
  • Fig. 22 Global hemophilia market: Therapy movement analysis
  • Fig. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
  • Fig. 24 Desmopressin & Fibrin sealants market estimates, 2018 - 2030 (USD Million)
  • Fig. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global hemophilia market: Regional movement analysis
  • Fig. 28 North America hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 32 UK hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 34 France hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 42 China hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 43 India hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 56 Strategy framework